Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
David Jin Insider Profile
11 Followers
David Jin, CFO at Fortress Biotech, holds 500.00 shares in Fortress Biotech (Ticker: FBIO), holds ― shares in Avenue Therapeutics (Ticker: ATXI). Most recently, David Jin Bought ― shares of Fortress Biotech on Jul 12, 2024 for an estimated value of 3.75K.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-35.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that David Jin holds in companies
Most Profitable Insider Trade
The most profitable trade made by David Jin
David Jin's Trading History
Fortress Biotech
Jul 12, 2024
CFO
Informative Buy
3.75K
$1.13K
Avenue Therapeutics
―
Interim PFO and COO
―
―
List of latest transactions for each holding click on a transaction to see David Jin's performance on stock
You May Also Like
David Jin insider profile FAQ
What is the percentage of profitable transactions made by David Jin?
The percentage of profitable transactions made by David Jin is 50%.
What is the average return per transaction made by David Jin?
The average return per transaction made by David Jin is -35.10%.
What stocks does David Jin hold?
David Jin holds: FBIO, ATXI stocks.
What was David Jin’s latest transaction?
David Jin latest transaction was an Informative Buy of $3.75K.
What was David Jin's most profitable transaction?
David Jin’s most profitable transaction was an Informative Buy of FBIO stock on July 12, 2024. The return on the trade was 11.30%.
What is David Jin's role in Fortress Biotech?
David Jin's role in Fortress Biotech is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.